{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:18:32Z","timestamp":1772777912398,"version":"3.50.1"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is a malignancy driven by the <jats:italic>BCR::ABL1<\/jats:italic>fusion gene, with the e19a2 transcript being a rare variant, accounting for 0.4% of CML cases. Patients with the e19a2 transcript often show poor response to first-line treatment with imatinib, and no standard therapy has been established for this subtype.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We report a case of a 28-year-old female with e19a2-positive CML. The patient exhibited poor response and tolerance to dasatinib. After 6\u202fmonths, she achieved partial cytogenetic response (PCyR) but developed grade 3 pleural effusion. Following treatment discontinuation and prednisone therapy, the patient continued dasatinib (80\u202fmg\/d). At 12\u202fmonths, the patient achieved complete cytogenetic response (CCyR), but <jats:italic>BCR::ABL1<\/jats:italic> levels remained suboptimal, with recurrent pleural effusion. The patient was then switched to flumatinib (600\u202fmg\/d), achieving major molecular response (MMR) at 6\u202fmonths and deep complete molecular response (MR4.5) at 24\u202fmonths, with good tolerance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Flumatinib demonstrated excellent deep molecular response and good tolerability in e19a2-positive CML patients, suggesting that it may be one of the preferred treatment options for such patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2025.1515002","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T07:18:03Z","timestamp":1742195883000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Molecular response of a patient with e19a2-positive chronic myeloid leukemia to flumatinib: a case report and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Yaqing","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongjin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinying","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiqin","family":"Mu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e2020062","DOI":"10.4084\/mjhid.2020.062","article-title":"Prognostic significance of transcript-type BCR - ABL1 in chronic myeloid leukemia","volume":"12","author":"Molica","year":"2020","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1182\/blood.V76.9.1819.1819","article-title":"New type of Bcr\/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia","volume":"76","author":"Saglio","year":"1990","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/s11684-018-0639-7","article-title":"Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety","volume":"13","author":"Huang","year":"2019","journal-title":"Front Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/bjh.15453","article-title":"Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single Centre","volume":"182","author":"Qin","year":"2018","journal-title":"Br J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1080\/10428194.2019.1607329","article-title":"Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts","volume":"60","author":"Xue","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.anndiagpath.2016.12.001","article-title":"Chronic myeloid leukemia with a rare fusion transcript, e19a2 BCR-ABL1: a report of three cases from India","volume":"27","author":"Sazawal","year":"2017","journal-title":"Ann Diagn Pathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"871476","DOI":"10.1155\/2013\/871476","article-title":"Early complete molecular response to first-line Nilotinib in two patients with chronic myeloid leukemia carrying the p230 transcript","volume":"2013","author":"Greco","year":"2013","journal-title":"Case Rep Hematol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.19746\/j.cnki.issn.1009-2137.2021.06.010","article-title":"Clinical effect of tyrosine kinase inhibitors in the treatment of P230 chronic myeloid leukemia","volume":"29","author":"Jiang","year":"2021","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","article-title":"Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3324\/haematol.2018.188987","article-title":"Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia","volume":"104","author":"Hughes","year":"2019","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"126758","DOI":"10.1016\/j.bmcl.2019.126758","article-title":"Structure-based analysis and biological characterization of imatinib derivatives reveal insights towards the inhibition of wild-type BCR-ABL and its mutants","volume":"29","author":"Yang","year":"2019","journal-title":"Bioorg Med Chem Lett"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3965","DOI":"10.3324\/haematol.2023.284892","article-title":"Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia","volume":"109","author":"Yang","year":"2024","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.clml.2024.02.008","article-title":"Comparison of the efficacy among Nilotinib, Dasatinib, Flumatinib and Imatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients: a real-world multi-center retrospective study","volume":"24","author":"Zhang","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1158\/1078-0432.CCR-20-1600","article-title":"Flumatinib versus Imatinib for newly diagnosed chronic phase chronic myeloid leukemia: a phase III, randomized, open-label","volume":"27","author":"Zhang","year":"2021","journal-title":"Multi-center FESTnd Study"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1515002\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T07:18:05Z","timestamp":1742195885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1515002\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":17,"alternative-id":["10.3389\/fmed.2025.1515002"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1515002","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"article-number":"1515002"}}